

## Ivermectin + Doxycycline vs Hydroxychloroquine + Azithromycin for COVID-19

**Author(s):** Cruciani F, De Crescenzo F, Vecchi S, Saulle R, Mitrova Z, Amato L, Davoli M.

**Question:** Should Ivermectin + Doxycycline compared to Hydroxychloroquine + Azithromycin be used for COVID-19?

**Setting:** Inpatient

Certainty assessment							№ of patients		Effect		Certainty
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Ivermectin + Doxycycline	Hydroxychloroquine + Azithromycin	Relative (95% CI)	Absolute (95% CI)	

### SARS-CoV-2 clearance

1 <sup>1</sup>	randomised trials	not serious	not serious	not serious	serious <sup>a</sup>	none	60/63 (95.2%)	54/62 (87.1%)	<b>RR 1.09</b> (0.98 to 1.22)	<b>78 more per 1.000</b> (from 17 fewer to 192 more)	⊕⊕⊕○ MODERATE
----------------	-------------------	-------------	-------------	-------------	----------------------	------	---------------	---------------	----------------------------------	---	------------------

### Number of patients with adverse events

1 <sup>1</sup>	randomised trials	not serious	not serious	not serious	serious <sup>a</sup>	none	19/63 (30.2%)	26/62 (41.9%)	<b>RR 0.72</b> (0.45 to 1.16)	<b>117 fewer per 1.000</b> (from 231 fewer to 67 more)	⊕⊕⊕○ MODERATE
----------------	-------------------	-------------	-------------	-------------	----------------------	------	---------------	---------------	----------------------------------	---	------------------

### Explanations

a. Abbassato di un livello per numerosità campionaria bassa.

### References

1. Chowdhury AT, Shahbaz M Karim Md R et al.. A Randomized Trial of Ivermectin-Doxycycline and Hydroxychloroquine-Azithromycin therapy on COVID19 patients.. PREPRINT (Version 1) available at Research Square [+<https://doi.org/10.21203/rs.3.rs-38896/v1>]